3-氟-5-羟基吡啶 | 209328-55-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-氟-5-羟基吡啶
• 中文别名: 5-氟-3-吡啶醇；3-羟基-5-氟吡啶；5-氟-3-羟基吡啶
• 英文名称: 5-fluoropyridin-3-ol
• 英文别名: 3-fluoro-5-hydroxypyridine
• CAS: 209328-55-2
• 化学式: C₅H₄FNO
• 分子量: 113.091
• InChiKey: IUFLFKASIHPKNZ-UHFFFAOYSA-N

物化性质

• 熔点：
  161-164℃
• 沸点：
  303.0±22.0 °C(Predicted)
• 密度：
  1.325±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S37
• 危险类别码：
  R22,R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
5-Fluoro-3-hydroxypyridine
Product Name:
Synonyms: 5-Fluoropyridin-3-ol

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Fluoro-3-hydroxypyridine
CAS number: 209328-55-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
This product should be handled only by, or under the close supervision of, those properly qualified
Handling:
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C5H4FNO
Molecular weight: 113.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  3-氟-5-异丙氧基吡啶	5-fluoro-3-isopropoxypyridine	213766-03-1	C8H10FNO	155.172

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  2-氯-3-羟基-5-氟吡啶	2-chloro-5-fluoropyridin-3-ol	884494-35-3	C5H3ClFNO	147.536
  2-氨基-5-氟-3-羟基吡啶	2-amino-5-fluoropyridin-3-ol	1003711-04-3	C5H5FN2O	128.106
  ——	2-((5-fluoropyridin-3-yl)oxy)acetonitrile	1542259-71-1	C7H5FN2O	152.128

反应信息

• 作为反应物：
  描述：

  3-氟-5-羟基吡啶 在 双氧水 、 溶剂黄146 作用下， 反应 15.25h， 以55%的产率得到5-fluoro-3-pyridinol N-oxide
  参考文献：
  名称：

  Novel thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therepeutics.

  摘要：

  这项发明涉及新型的5-硫氧木糖化合物，优选为5-硫氧木糖吡喃糖类衍生物，以及它们的制备方法，以及它们作为药物活性成分的用途，特别用于治疗或预防血栓或心脏功能不全。

  公开号：

  US20070054955A1
• 作为产物：
  描述：

  5-isopropyloxypyridine-3-amine 在 吡啶 、 氢氟酸 、 氢溴酸 、 sodium nitrite 作用下， 以 溶剂黄146 为溶剂， 反应 73.5h， 生成 3-氟-5-羟基吡啶
  参考文献：
  名称：

  2-，5-和6-卤代-3-（2（S）-氮杂环丁烷基甲氧基）吡啶：合成，对烟碱乙酰胆碱受体的亲和力和分子模型。

  摘要：

  3-（2（S）-氮杂环丁烷基甲氧基）吡啶（A-85380）最近被鉴定为对烟碱乙酰胆碱受体（nAChRs）具有高亲和力的配体。在这里，我们报告的合成和体外nAChR结合的一系列10吡啶修饰的A-85380类似物。新化合物在3-吡啶基片段的2、5或6位具有卤素取代基。那些在5或6位具有取代基的化合物以及2-氟类似物对大鼠脑膜中的nAChR具有亚纳摩尔亲和力。对于这些配体，通过与（+/-）-[3H]表巴替丁竞争测定，Ki值范围为11至210pM。相反，2-氯，2-溴和2-碘类似物表现出低得多的亲和力。AM1量子化学计算表明，位置2的庞大取代基会引起分子几何结构的显着变化。该系列的高亲和力成员和（+）-依巴替丁显示出低能量稳定构象异构体的紧密配合叠加。对nAChRs具有高亲和力的新配体可能会作为药理探针，潜在药物以及开发放射性卤化示踪剂研究nAChRs的候选药物而引起人们的兴趣。

  DOI：

  10.1021/jm980170a

文献信息

• Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20140128372A1

  公开（公告）日：2014-05-08

  The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

  本申请涉及新型取代咪唑[1,2-a]吡啶-3-羧酰胺，其制备方法，单独或组合使用以治疗和/或预防疾病，以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019243527A1

  公开（公告）日：2019-12-26

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病的用途，例如tau病变，特别是阿尔茨海默病或进行性核上性麻痹症；以及伴有tau病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩侧索硬化或额颞叶痴呆症。
• TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF
  申请人：Merck Patent GmbH

  公开号：US20160376283A1

  公开（公告）日：2016-12-29

  The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.

  本发明涉及式I化合物及其药用可接受的组合物，用作TBK/IKKε抑制剂。
• [EN] SUBSTITUTED IMIDAZOPYRIDINE AND TRIAZOLOPYRIDINE COMPOUNDS AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR5<br/>[FR] COMPOSÉS IMIDAZOPYRIDINE ET TRIAZOLOPYRIDINE SUBSTITUÉS UTILISÉS COMME MODULATEURS ALLOSTÉRIQUES NÉGATIFS DE MGLUR
  申请人：UNIV VANDERBILT

  公开号：WO2015077246A1

  公开（公告）日：2015-05-28

  Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本文披露了代谢型谷氨酸受体亚型5（mGluR5）的负向变构调节剂；制备这些化合物的合成方法；包含这些化合物的药物组合物；以及使用这些化合物和组合物治疗与谷氨酸功能障碍相关的神经和精神疾病的方法。本摘要旨在作为在特定领域进行搜索的扫描工具，并不意在限制本发明。
• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE LA KINASE RET
  申请人：ANDREWS STEVEN W

  公开号：WO2018071454A1

  公开（公告）日：2018-04-19

  Provided herein are compounds of the Formula I: (I) or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  本文提供了Formula I的化合物：(I)或其药用可接受的盐或溶剂，其中A、B、X1、X2、X3、X4、环D、E、Ra、Rb、n和m的含义如规范中所述，它们是RET激酶的抑制剂，并且在治疗和预防可以用RET激酶抑制剂治疗的疾病中非常有用，包括与RET相关的疾病和紊乱。